Poseida Therapeutics' unique approach to gene editing and delivery addresses some of the major obstacles faced within cell and gene therapy...

This week’s clinical update looks at a Phase 1/2 trial for a CRISPR-edited checkpoint cell therapy for difficult-to-treat gastrointestinal cancers...

Two weeks ago, we hosted a CMN webinar on CRISPR Delivery Systems. Several hundred attendees from all continents tuned in for the live event. Here's a...

This week’s update looks at a combined vaccine/CRISPR-edited T cell trial for prostate cancer, and a CRISPR-edited CAR-T cell trial for non-small cell...

Update on Allogene Therapeutics off-the-shelf CAR-T cancer therapies. This week’s gene-editing update looks at an investigational new drug (IND)...

Lack of efficient delivery vehicles has so far hampered CRISPR-Cas9 editing in non-liver tumours. With a new lipid nanoparticle delivery system,...

Last week, we bought you our first IND update for a selection of gene-editing therapies currently under development for blood disorders. This week, we...

Clinical trials to assess the safety and medical benefit of CRISPR therapies are complex. This is not only because they explore a novel technology,...